<DOC>
	<DOCNO>NCT00932893</DOCNO>
	<brief_summary>This Phase 3 trial compare safety anti-tumor activity PF-02341066 versus pemetrexed docetaxel patient advance non-small cell lung cancer specific gene profile involve ALK gene failure one previous chemotherapy regimen include one platinum drug .</brief_summary>
	<brief_title>An Investigational Drug , PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase ( ALK ) Gene</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>histologically cytologically proven diagnosis nonsmall cell lung cancer positive ALK fusion gene ( test provide central laboratory ) must disease progression one prior chemotherapy regimen must include one platinum drug tumor must measurable prior treatment PF02341066 current treatment another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Lung Neoplasms ALK gene crizotinib</keyword>
</DOC>